Evotec SE Updates FY25 Revenue Guidance, Confirms Profit Guidance

Evotec SE adjusts its revenue guidance for FY25 to €760-800m, citing a change in revenue mix and cost savings. R&D expenditures are expected to be €40-50m and adjusted EBITDA is expected to reach €30-50m. The company's guidance on R&D expenses and adjusted EBITDA remains unchanged. The revised guidance is due to a stronger contribution from technology licensing and a challenging market environment for the Shared R&D base business.

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) has revised its revenue guidance for fiscal year 2025 (FY25) to €760-800 million, citing a change in revenue mix and significant cost savings. The company's guidance on Research & Development (R&D) expenditures and adjusted EBITDA remains unchanged at €40-50 million and €30-50 million, respectively. The revised guidance reflects a stronger contribution from technology licensing and a challenging market environment for the Shared R&D base business.

The primary reasons for the refined guidance include a shift in the revenue mix and successful cost-saving initiatives from the Priority Reset program. Technology licensing, a key pillar of Evotec's strategic repositioning, is expected to make a stronger contribution. However, the Shared R&D base business is anticipated to operate in a challenging market environment in the second half of 2025. Group revenues were below expectations in the first half of 2025, while adjusted EBITDA remained broadly in line with projections. Actions are underway to transform the business towards sustainable profitable growth.

Evotec SE, based in Hamburg, Germany, is a biotechnology company focusing on the development of innovative medicines and technologies. The company's strategic focus includes technology licensing and the Shared R&D base business, which collaborates with pharmaceutical companies to advance drug discovery and development.

References:

[1] https://www.tradingview.com/news/eqs:1977b1e29094b:0-evotec-se-adjusts-revenue-guidance-while-confirming-profit-guidance/
[2] https://finance.yahoo.com/news/favorable-government-support-fuels-germanys-080900644.html
[3] https://www.stocktitan.net/news/EVO/evotec-se-adjusts-revenue-guidance-while-confirming-profit-lwfvvmey18ex.html